Search

Your search keyword '"B. Lequeux"' showing total 19 results
Start Over Author "B. Lequeux"
19 results on '"B. Lequeux"'

3. Demographic characteristics of the 1902 transthyretin amyloid cardiomyopathy patients treated by tafamidis through the French early access program

Author

C Noirot-Cosson, B Lequeux, Thibaud Damy, J Jeanneteau, Jean-Christophe Eicher, Patricia Reant, Mounira Kharoubi, Gilbert Habib, J. Rudant, Olivier Lairez, Fabrice Bauer, A Jobbe Duval, and M. Bartoli

Subjects
Tafamidis, chemistry.chemical_compound, Transthyretin, medicine.medical_specialty, chemistry, biology, business.industry, Internal medicine, biology.protein, medicine, Cardiology and Cardiovascular Medicine, business, Amyloid cardiomyopathy
Abstract

Background Transthyretin amyloidosis (ATTR) is a rare and serious, systemic disease characterized by deposits of amyloid fibrils in various tissues and organs. Tafamidis meglumine is a potent and selective stabilizer of TTR, indicated since 2011 in the treatment of neurological forms of the disease. The French “Agence Nationale de Sécurité du Médicament et des produits de santé” (ANSM) granted a temporary recommendation for use (RTU) on November 28th 2018, based on ATTR-ACT, the pivotal trial results, and designed to enable use of tafamidis meglumine in ATTR cardiomyopathy (ATTR-CM) patients with NYHA I, II and III before marketing authorization. This RTU has been a unique opportunity in France to collect real world data of ATTR-CM patients treated by tafamidis meglumine. Objective We aimed to describe the characteristics of ATTR-CM patient treated by tafamidis in the setting of the RTU, over 2 years from November 28th 2018 to November 27th 2020. Methods Demographic and clinical data about the diagnosis pathway of patients included in the RTU were prospectively collected using questionnaires, as requested by ANSM to be completed by physicians at the time of tafamidis prescription. A second version of the inclusion form, introduced in May 2020, has allowed collection of additional clinical information. Results Overall, 1902 ATTR-CM patients have been included by 189 physicians from 107 centers. Nine centers included each at least 50 patients, accounting for 1092, or 57.4% of all patients. The median age of the patients was 82 years (IQR=9 years), 82% were male, and, 12.4%, 58.8% and 28.7% of patients had a NYHA class of I, II and III, respectively. For almost all patients, the diagnosis of restrictive/infiltrative heart failure was based on heart MRI and/or echocardiography (98.5%; among the 601 patients included from May 2020 28.8% had both exams, 69.7% echo only and 1.6% MRI only), the infiltrative nature of the cardiomyopathy had been confirmed by bone scintigraphy (99.3%), and the absence of light chains had been confirmed by protein electrophoresis or Bence Jones proteinuria (96.6%). Genetic test was performed in 1205 patients (69.4%). Out of the 884 patients who had a genetic test result available at the time of initial prescription, 762 (86.2%) were affected with the wild-type form and 122 (13.8%) with the hereditary form. Among the 601 patients included from May 2020, a hospitalization for cardiovascular condition within the 6 months preceding tafamidis initiation was reported for 22.3% of them, and tafamidis was initiated within 12 months after diagnosis for 92% of them (only 8% initiated the treatment beyond that period). Conclusion The RTU program has provided 1902 ATTR-CM patients with early access to tafamidis over 24 months, in France. Overall, as compared to patients included in ATTR-ACT, the pivotal trial, RTU patients were older, the proportion of wild-type was slightly higher, and NYHA distributions were similar. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): Early access program sponsored by Pfizer

Published
2021

4. Is there a white-coat effect for heart rate in heart failure? Characteristics and prognostic implications in patients with idiopathic dilated cardiomyopathy

Author

B. Lequeux, Arnaud Bisson, Nicolas Clementy, Laurent Fauchier, Bertrand Pierre, M. Boyer, Denis Angoulvant, and Dominique Babuty

Subjects
medicine.medical_specialty, business.industry, Heart failure, Internal medicine, Heart rate, Idiopathic dilated cardiomyopathy, Cardiology, Medicine, In patient, Cardiology and Cardiovascular Medicine, business, medicine.disease, White coat effect
Published
2017

5. Poster Session 3: Friday 9 December 2011, 08:30-12:30 * Location: Poster Area

Author

C. Kenny, S. Adhya, R. Dworakowski, B. Brickham, P. Maccarthy, M. Monaghan, A. Guzzo, F. Innocenti, S. Vicidomini, D. Lazzeretti, S. Squarciotta, E. De Villa, C. Donnini, F. Bulletti, E. Guerrini, R. Pini, K. Bendjelid, J. Viale, S. Duperret, V. Piriou, D. Jacques, K. Shahgaldi, C. Silva, F. Pedro, L. Deister, L.-A. Brodin, A. Sahlen, A. Manouras, R. Winter, N. Berjeb, C. Cimadevilla, J. Dreyfus, C. Cueff, M. Malanca, A. Chiampan, A. Vahanian, D. Messika-Zeitoun, D. Muraru, D. Peluso, L. Dal Bianco, M. Beraldo, E. Solda', M. Tuveri, U. Cucchini, A. Al Mamary, L. Badano, S. Iliceto, I. Almuntaser, G. King, S. Norris, C. Daly, E. Ellis, R. Murphy, T. Erdei, M. Denes, A. Kardos, C. Foldesi, A. Temesvari, M. Lengyel, A. Bouzas Mosquera, F. Broullon, N. Alvarez-Garcia, J. Peteiro, G. Barge-Caballero, M. Lopez-Perez, A. Lopez-Sainz, A. Castro-Beiras, M. Luotolahti, H. Luotolahti, I. Kantola, J. Viikari, M. Andersen, M. Ersboell, J. Bro-Jeppesen, F. Gustafsson, L. Koeber, C. Hassager, J. Moller, D. Coisne, C. Diakov, F. Vallet, B. Lequeux, P. Blouin, L. Christiaens, R. Esposito, A. Santoro, V. Schiano Lomoriello, R. Raia, C. Santoro, G. De Simone, M. Galderisi, G. Abdula, W. Kosmala, H. Szczepanik-Osadnik, M. Przewlocka-Kosmala, A. Mysiak, T. O' Moore-Sullivan, T. Marwick, Y. T. Tan, F. Wenzelburger, F. Leyva, J. Sanderson, P. Pichler, B. Syeda, P. Hoefer, A. Zuckermann, T. Binder, M. Fijalkowski, A. Koprowski, R. Galaska, K. Blaut, K. Sworczak, A. Rynkiewicz, S. Lee, W. Kim, L. Jung, H. Yun, M. Song, J. Ko, E. A. Khalifa, P. Szymanski, M. Lipczynska, A. Klisieiwcz, P. Hoffman, C. Jorge, J. Silva Marques, S. Robalo Martins, C. Calisto, M. Mieiro, S. Vieira, M. Correia, J. Carvalho De Sousa, A. Almeida, A. Nunes Diogo, C. Park, K. March, T. Tillin, J. Mayet, N. Chaturvedi, A. Hughes, V. Di Bello, C. Giannini, M. Delle Donne, F. De Sanctis, P. Spontoni, C. Cucco, A. Corciu, C. Grigoratos, F. Bogazzi, A. Balbarini, O. Enescu, B. Suran, M. Florescu, M. Cinteza, D. Vinereanu, Y. Higuchi, K. Iwakura, A. Okamura, M. Date, K. Fujii, N. Cortez-Dias, D. Silva, P. Carrilho-Ferreira, A. Magalhaes, S. Ribeiro, S. Goncalves, M. Fiuza, F. Pinto, R. Placido, A. Bordalo, P. Grzywocz, K. Mizia-Stec, J. Chudek, Z. Gasior, A. M. Maceira Gonzalez, J. Cosin Sales, E. Dalli, B. Igual, J. Diago, J. Aguilar, J. Ruvira, S. Cimino, G. Pedrizzetti, G. Tonti, E. Canali, V. Petronilli, F. Boccalini, A. Mattatelli, Y. Hiramoto, C. Iacoboni, L. Agati, D. Trifunovic, M. Ostojic, B. Vujisic-Tesic, M. Petrovic, I. Nedeljkovic, M. Banovic, M. Boricic-Kostic, G. Draganic, M. Tesic, C. Gavina, R. Lopes, A. Lourenco, J. Almeida, J. Rodrigues, P. Pinho, J. Zamorano, A. Leite-Moreira, F. Rocha-Goncalves, M.-A. Clavel, R. Capoulade, J. Dumesnil, P. Mathieu, J.-P. Despres, P. Pibarot, S. Bull, A. Pitcher, D. Augustine, J. D'arcy, T. Karamitsos, A. Rai, B. Prendergast, H. Becher, S. Neubauer, S. Myerson, J. Magne, E. Donal, L. Davin, K. O'connor, C. Pirlet, M. Rosca, C. Szymanski, B. Cosyns, L. Pierard, P. Lancellotti, A. Calin, B. Popescu, C. Beladan, R. Enache, L. Lupascu, C. Sandu, C. Ginghina, V. Kamperidis, S. Hadjimiltiadis, G. Sianos, K. Anastasiadis, V. Grosomanidis, G. Efthimiadis, H. Karvounis, G. Parharidis, I. Styliadis, C. Gonzalez Canovas, C. Munoz-Esparza, J. Bonaque Gonzalez, A. Fernandez, M. Salar Alcaraz, D. Saura Espin, E. Pinar Bermudez, M. Oliva-Sandoval, G. De La Morena Valenzuela, M. Valdes Chavarri, E. Brochet, L. Lepage, D. Attias, D. Detaint, D. Himbert, B. Iung, B. Pirat, S. Little, S. Chang, L. Tiller, R. Kumar, W. Zoghbi, A. P.-W. Lee, M. Hsiung, S. Wan, R. Wong, F. Luo, F. Fang, J. Xie, M. Underwood, J. Sun, C. Yu, R. Jansen, W. Tietge, K. Sijbrandij, M. Cramer, L. De Heer, J. Kluin, S. A. J. Chamuleau, T. Oliveras Vila, E. Ferrer Sistach, L. Delgado Ramis, J. Lopez Ayerbe, N. Vallejo Camazon, F. Gual Capllonch, C. Garcia Alonso, A. Teis Soley, X. Ruyra Baliarda, A. Bayes Genis, S. Negrea, C. Alexandrescu, F. Bourlon, F. Civaia, G. Dreyfus, S. Paetzold, O. Luha, R. Hoedl, G. Stoschitzky, K. Pfeiffer, D. Zweiker, B. Pieske, R. Maier, T. Sevilla, A. Revilla, J. Lopez, I. Vilacosta, R. Arnold, I. Gomez, J. San Roman, G. Nikcevic, A. Djordjevic Dikic, S. Djordjevic, S. Raspopovic, V. Jovanovic, B. Kircanski, S. Pavlovic, G. Milasinovic, I. Ruiz-Zamora, F. Cabrera Bueno, M. Molina, J. Fernandez-Pastor, J. Pena, A. Linde, A. Barrera, J. Alzueta, C. Bremont, A. Bensaid, H. Alonso, O. Zaghden, J. Nahum, J. Dubois-Rande, P. Gueret, P. Lim, S.-P. Lee, K. Park, H.-R. Kim, J.-H. Lee, H.-S. Ahn, J.-H. Kim, H.-K. Kim, Y.-J. Kim, D.-W. Sohn, M. Niemann, S. Herrmann, K. Hu, D. Liu, M. Beer, G. Ertl, C. Wanner, T. Takenaka, C. Tei, F. Weidemann, H. Madeira, M. Mendes Pedro, D. Brito, R. Ippolito, D. De Palma, S. Gati, D. Oxborough, M. Reed, A. Zaidi, S. Ghani, N. Sheikh, M. Papadakis, S. Sharma, V. Chow, A. Ng, T. Pasqualon, W. Zhao, D. Hanzek, T. Chung, T. Yeoh, L. Kritharides, L. Magda, D. Mihalcea, D. Jinga, R. Mincu, E. Ferrazzi, G. Segato, F. Folino, G. Famoso, M. Senzolo, R. Bellu, F. Corbetti, F. Tona, O. Azevedo, I. Quelhas, J. Guardado, M. Fernandes, V. Pereira, R. Medeiros, P. Sousa, W. Santos, S. Pereira, N. Marques, J. Mimoso, V. Marques, I. Jesus, L. Rustad, K. Nytroen, L. Gullestad, B. Amundsen, S. Aakhus, K. Linhartova, G. Sterbakova, J. Necas, S. Kovalova, R. Cerbak, N. Nelassov, N. Korotkijan, A. Shishkina, B. Gagieva, M. Nagaplev, O. Eroshenko, M. Morgunov, S. Parmon, S. Velthuis, M. Van Gent, M. Post, C. Westermann, J. Mager, R. Snijder, S. P. Koyalakonda, M. Anderson, M. Burgess, L. Bergenzaun, M. Chew, H. Ohlin, G. F. Gjerdalen, J. Hisdal, E. Solberg, T. Andersen, Z. Radunovic, K. Steine, T. Rutz, A. Kuehn, K. Petzuch, M. Pekala, J. Elmenhorst, S. Fratz, J. Mueller, A. Hager, J. Hess, M. Vogt, D. Van Der Linde, I. Van De Laar, M. Wessels, J. Bekkers, A. Moelker, H. Tanghe, F. Van Kooten, R. Oldenburg, A. Bertoli-Avella, J. Roos-Hesselink, A. Cresti, L. Fontani, P. Calabria, E. Capati, S. Severi, M. Lynch, S. Saraf, B. Sandler, S. Yoon, S. Kim, C. Ko, S. Ryu, Y. Byun, H. Seo, Q. Ciampi, F. Rigo, L. Pratali, S. Gherardi, B. Villari, E. Picano, R. Sicari, J. Celutkiene, D. Zakarkaite, V. Skorniakov, V. Zvironaite, V. Grabauskiene, J. Sinicyna, G. Gruodyte, K. Janonyte, A. Laucevicius, J. O'driscoll, K. Schmid, A. Marciniak, A. Saha, S. Gupta, R. Smith, R. Sharma, N. Alvarez Garcia, O. Prada, A. Rodriguez Vilela, G. Barge Caballero, M. Lopez Perez, A. Lopez Sainz, A. Castro Beiras, J. Kochanowski, P. Scislo, R. Piatkowski, M. Grabowski, M. Marchel, M. Roik, D. Kosior, G. Opolski, C. M. Van De Heyning, H. Mahjoub, H. Clausen, C. Basaggianis, J. Newton, A. Del Pasqua, A. Carotti, D. Di Carlo, E. Cetrano, A. Toscano, R. Iacobelli, C. Esposito, M. Chinali, G. Pongiglione, G. Rinelli, M. Larsson, A. Bjallmark, K. Caidahl, L. Brodin, H. Gao, M. Lugiez, C. Guivier, R. Rieu, J. D'hooge, G. Hang, C. Guerin, M. Menard, J.-U. Voigt, J. Dungu, G. Campos, R. Jaffarulla, S. Gomes-Pereira, N. Sutaria, C. Baker, P. Nihoyannopoulos, M. Bellamy, D. Harries, N. Walker, P. Pearson, J. Reiken, J. Batteson, R. Kamdar, F. Murgatroyd, A. D'andrea, L. Riegler, R. Scarafile, E. Pezzullo, G. Salerno, E. Bossone, G. Limongelli, M. Russo, G. Pacileo, R. Calabro', Y. Kang, J. Cui, H. Chen, C. Pan, X. Shu, A. Kiotsekoglou, S. Saha, R. Toole, S. Govind, A. Gopal, F. Crispi, B. Bijnens, E. Sepulveda-Swatson, J. Rojas-Benavente, J. Dominguez, M. Illa, E. Eixarch, M. Sitges, E. Gratacos, C. Prinz, R. Faludi, A. Walker, M. Amzulescu, T. Uejima, A. Fraser, J. Voigt, M. Esmaeilzadeh, M. Maleki, A. Amin, F. Vakilian, F. Noohi, Z. Ojaghi Haghighi, P. Nakhostin Davari, H. Bakhshandeh Abkenar, R. Rimbas, R. Dulgheru, A. Margulescu, M. D' Asaro, C. Mizzon, F. Parisi, B.-C. Jung, B.-Y. Lee, H.-J. Kang, M. Kim, Y. Kim, D. Cho, S. Park, S. Hong, D. Lim, W. Shim, H. Bellsham-Revell, S. Tibby, A. J. Bell, O. I. Miller, G. Greil, J. M. Simpson, R. A. Providencia, J. Trigo, A. Botelho, P. Gomes, L. Seca, S. Barra, A. Faustino, G. Costa, N. Quintal, A. Leitao-Marques, E. Nestaas, A. Stoylen, D. Fugelseth, C. Mornos, A. Ionac, L. Petrescu, D. Cozma, D. Dragulescu, A. Mornos, S. Pescariu, A. Fontana, M. Abbate, M. Cazzaniga, C. Giannattasio, G. Trocino, K. Laser, L. Faber, M. Fischer, H. Koerperich, D. Kececioglu, M. F. Elnoamany, A. Dawood, M. Elhabashy, Y. Khalil, N. Piriou, K. Warin-Fresse, M. Caza, G. Fau, D. Crochet, N. Xhabija, I. Allajbeu, E. Petrela, M. Heba, M. Barreiro Perez, M. Martin Fernandez, A. Renilla Gonzalez, J. Florez Munoz, O. Fernandez Cimadevilla, I. Alvarez Pichel, E. Velasco Alonso, D. Leon Duran, E. Benito Martin, S. Secades Gonzalez, L. Gargani, P. Pang, E. Davis, A. Schumacher, A. Silva Ferreira, N. Bettencourt, P. Matos, L. Oliveira, J. Cosin-Sales, M. Lopez Lereu, J. Monmeneu, J. Estornell, M. Tsverava, D. Tsverava, A. Varela, M. Salagianni, I. Galani, E. Andreakos, C. Davos, I. Ikonomidis, J. Lekakis, V. Tritakis, N. Kadoglou, J. Papadakis, P. Trivilou, S. Tzortzis, C. Koukoulis, I. Paraskevaidis, M. Anastasiou-Nana, G. Kim, H. Youn, P. Ibrahimi, G. Bajraktari, F. Jashari, A. Ahmeti, A. Poniku, E. Haliti, M. Henein, B. Pezo Nikolic, H. Jurin, D. Lovric, Z. Baricevic, I. Ivanac Vranesic, M. Lovric Bencic, A. Ernst, and J. Separovic Hanzevacki

Subjects
Novel technique, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, Computer vision, Nanotechnology, General Medicine, Contrast (music), Artificial intelligence, Cardiology and Cardiovascular Medicine, business
Published
2011

6. Poster session V * Saturday 11 December 2010, 08:30-12:30

Author

Q. H. Pham, T. G. Von Lueder, S. K. Namtvedt, H. Rosjo, T. Omland, K. Steine, A. T. Timoteo, M. Mota Carmo, M. Simoes, L. M. Branco, R. C. Ferreira, R. Kato, J. Ito, T. Tahara, Y. Yokoyama, T. Ashikaga, Y. Satoh, J. O. Na, H. E. Hong, M. N. Kim, S. Y. Shin, C. U. Choi, E. J. Kim, S. W. Rha, C. G. Park, H. S. Seo, D. J. Oh, R. Ticulescu, S. Brigido, O. Vriz, L. Sparacino, B. A. Popescu, C. Ginghina, S. Carerj, G. L. Nicolosi, F. Antonini-Canterin, J. J. Onaindia Gandarias, A. Romero, E. Laraudogoitia, S. Velasco, O. Quintana, A. Cacicedo, I. Rodriguez, J. A. Alarcon, J. Gonzalez, I. Lekuona, A. Subinas, G. Abdula, L. H. Lund, R. Winter, L. Brodin, A. Sahlen, M. Masaki, Y. M. Cha, T. Yuasa, K. Dong, Y. X. Dong, S. V. Mankad, J. K. Oh, F. Vallet, B. Lequeux, C. Diakov, P. Sosner, L. Christiaens, D. Coisne, C. Kihara, K. Murata, Y. Wada, K. Uchida, T. Ueyama, S. Okuda, T. Susa, M. Matsuzaki, E. J. Cho, K. Y. Choi, B. J. Kwon, D. B. Kim, S. W. Jang, J. S. Cho, H. O. Jung, H. K. Jeon, H. J. Youn, J. H. Kim, M. Cikes, B. Bijnens, V. Velagic, T. Kopjar, D. Milicic, B. Biocina, H. Gasparovic, I. Almuntaser, A. Brown, B. Foley, N. Mulvihill, P. Crean, G. King, R. Murphy, Y. Takata, M. Taniguchi, S. Nobusada, M. Sugawara, N. Toh, K. Kusano, H. Itoh, E. Wellnhofer, C. Kriatselis, S. Nedios, J. H. Gerds-Li, E. Fleck, M. K. Poulsen, J. E. Henriksen, J. Dahl, A. Johansen, T. Haghfelt, P. F. Hoilund-Carlsen, H. Beck-Nielsen, J. E. Moller, R. Dankowski, M. Wierzchowiecki, M. Michalski, A. Nowicka, K. Szymanowska, A. Pajak, K. Poprawski, A. Szyszka, M. Kasner, D. Westermann, H. P. Schultheiss, C. Tschoepe, T. Watanabe, M. Iwai-Takano, A. Kobayashi, H. Machii, Y. Takeishi, B. P. Paelinck, P. L. Van Herck, J. M. Bosmans, C. J. Vrints, H. J. Lamb, A. Doltra, B. Vidal, E. Silva, S. Poyatos, L. Mont, A. Berruezo, A. Castel, J. M. Tolosana, J. Brugada, M. Sitges, M. Dencker, O. Bjorgell, J. Hlebowicz, Z. S. Szelenyi, G. Szenasi, M. Kiss, Z. Prohaszka, A. Patocs, I. Karadi, A. Vereckei, S. K. Saha, P. L. Anderson, S. Govind, M. Govindan, J. C. Moggridge, A. Kiotsekoglou, A. S. Gopal, B. B. Loegstrup, T. B. Christophersen, D. E. Hoefsten, J. E. Moeller, H. E. Boetker, K. Egstrup, M. Graefe, F. Q. Huang, R. S. Zhang, T. T. Le, R. S. Tan, R. Sattarzadeh Badkoubeh, A. Tavoosi, A. R. Elahian, O. Drapkina, V. I. Ivashkin, A. Fazakas, L. Pepo, O. Janosi, I. Kopitovic, A. Goncalves, P. Marcos-Alberca, C. Almeria, G. Feltes, E. Rodriguez, E. Garcia, R. Hernandez-Antolin, C. Macaya, J. Silva Cardoso, J. L. Zamorano, M. S. Navarro, M. Valentin, C. M. Banes, F. Rigo, E. Grolla, F. Tona, V. Cuaia, A. Moreo, L. Badano, A. Raviele, S. Iliceto, P. Tarzia, A. Sestito, R. Nerla, A. Di Monaco, F. Infusino, D. Matera, F. Greco, R. M. Tacchino, G. A. Lanza, F. Crea, A. Nemes, E. Balazs, K. S. Pinter, A. Egyed, M. Csanady, T. Forster, E. Holte, J. Vegsundvag, T. Hole, K. Hegbom, R. Wiseth, D. Sharif, A. Sharif-Rasslan, C. Shahla, A. Khalil, U. Rosenschein, A. Zagatina, N. Zhuravskaya, T. V. Tyurina, E. Tagliamonte, T. Cirillo, A. Coppola, U. Marinelli, C. Romano, G. Riccio, R. Citro, C. Astarita, N. Capuano, G. Quaranta, A. Desiderio, S. Frattini, P. Faggiano, V. Zilioli, E. Locantore, S. Longhi, F. Bellandi, G. Faden, M. Triggiani, L. Dei Cas, M. Dalsgaard, J. Kjaergaard, K. Iversen, C. Hassager, W. Dinh, W. N. Nickl, J. S. Smettan, T. K. Koehler, T. D. Scheffold, M. C. B. Coll Barroso, J. G. Guelker, R. F. Fueth, V. Kamperidis, S. Hadjimiltiades, G. Sianos, G. Efthimiadis, H. Karvounis, G. Parcharidis, I. H. Styliadis, M. S. Velasco Del Castillo, J. J. Onaindia, M. Telleria, H. G. Carstensen, C. Nordenberg, P. Sogaard, T. Fritz-Hansen, J. Bech, S. Galatius, J. S. Jensen, R. Mogelvang, P. E. Bartko, S. Graf, R. Rosenhek, I. G. Burwash, J. Bergler-Klein, M.-A. Clavel, H. Baumgartner, P. Pibarot, G. Mundigler, B. Kirilmaz, I. Eser, N. Tuzun, B. Komur, H. Dogan, A. Taskiran Comez, E. Ercan, M. Cusma-Piccione, C. Zito, G. Oreto, S. Piluso, S. Tripepi, L. Oreto, C. Longordo, L. Ciraci, G. Di Bella, R. Piatkowski, J. Kochanowski, P. Scislo, M. Grabowski, M. Marchel, M. Roik, D. Kosior, G. Opolski, L. Sknouril, M. Dorda, B. Holek, L. Gajdusek, J. Chovancik, M. Branny, M. Fiala, P. Szymanski, M. Lipczynska, A. Klisiewicz, P. Hoffman, N. Jander, J. Minners, G. Martin, W. Zeh, M. Allgeier, C. Gohlke-Baewolf, H. Gohlke, S. Nistri, M. C. Porciani, M. Attanasio, R. Abbate, G. F. Gensini, G. Pepe, R. F. Duncan, C. Piantadosi, A. J. Nelson, G. Wittert, B. Dundon, M. I. Worthley, S. G. Worthley, P. Jung, K. Berlinger, J. Rieber, H. Z. Sohn, P. Schneider, M. Leibig, A. Koenig, V. Klauss, L. Tomkiewicz-Pajak, J. Kolcz, M. Olszowska, M. Pieculewicz, P. Podolec, T. Przewlocki, E. Suchon, B. Sobien, P. Wilkolek, A. Ziembicka, M. Hlawaty, A. Van De Bruaene, H. Hermans, R. Buys, L. Vanhees, M. Delcroix, J.-U. Voigt, W. Budts, E. De Cillis, T. Acquaviva, D. Basile, A. S. Bortone, D. Kalimanovska-Ostric, T. Nastasovic, B. Vujisic-Tesic, I. Jovanovic, B. Milakovic, M. Dostanic, M. Stosic, A. Frogoudaki, K. Andreou, J. Parisis, E. Triantafyllidi, S. Gaitani, J. Paraskevaidis, M. Anastasiou-Nana, G. De Pasquale, A. Kuehn, K. Petzuch, J. Mueller, C. Meierhofer, S. Fratz, A. Hager, J. Hess, M. Vogt, C. H. Attenhofer Jost, J. A. Dearani, C. G. Scott, H. M. Burkhart, H. M. Connolly, A. Vitarelli, D. Battaglia, F. Caranci, V. Padella, G. Continanza, O. Dettori, L. Capotosto, M. Vitarelli, V. De Cicco, M. Cortez Morichetti, K. K. Mohanan Nair, B. Sasidaharan, A. Thajudeen, J. M. Tharakan, L. Mertens, N. Ahmad, P. K. Kantor, L. Grosse-Wortmann, M. K. Friedberg, Y. F. Bernard, M. A. Morel, V. Descotes-Genon, J. Jehl, N. Meneveau, F. Schiele, M. Kaldararova, I. Simkova, P. Tittel, J. Masura, O. Trojnarska, L. Szczepaniak, K. Mizia -Stec, A. Cieplucha, A. Bartczak, S. Grajek, A. Tykarski, Z. Gasior, D. Babovicvuksanovic, C. R. Bonnichsen, G. J. Morgan, C. Slorach, W. Hui, T. Sarkola, K. J. Lee, R. Chaturvedi, L. Benson, T. Bradley, M. E. Iancu, I. Ghiorghiu, M. Serban, I. Craciunescu, A. Hodo, J. Morgan, L. Roche, K. Lee, O. Milanesi, V. Favero, M. Padalino, R. Biffanti, A. Cerutti, N. Maschietto, E. Reffo, V. Vida, G. Stellin, O. Irtyuga, D. Gamazin, I. Voronkina, N. Tsoyi, E. Gudkova, O. Moiseeva, C. Aggeli, C. Kazazaki, I. Felekos, S. Lagoudakou, G. Roussakis, J. Skoumas, C. Pitsavos, C. Stefanadis, C. Cueff, N. Keenan, P. G. Steg, C. Cimadevilla, G. Ducrocq, A. Vahanian, D. Messika-Zeitoun, L. Petrella, A. M. Mazzola, C. V. Villani, R. G. Giancola, M. C. Ciocca, D. E. M. Di Eusanio, S. Nolan, A. Ionescu, T. R. Skaug, B. H. Amundsen, T. Hergum, H. Torp, B. O. Haugen, J. Lopez Aguilera, D. Mesa Rubio, M. Ruiz Ortiz, M. Delgado Ortega, E. Villanueva Fernandez, L. Cejudo Diaz Del Campo, F. Toledano Delgado, M. Leon Del Pino, E. Romo Pena, J. Suarez De Lezo Cruz-Conde, E. De Marco, A. Colucci, G. Comerci, F. A. Gabrielli, R. Natali, B. Garramone, M. Savino, M. Lotrionte, A. Sonaglioni, F. Loperfido, M. Zdravkovic, J. Perunicic, M. Krotin, M. Ristic, V. Vukomanovic, M. Zaja, S. Radovanovic, J. Saric, D. Zdravkovic, C. Cotrim, A. R. Almeida, R. Miranda, A. G. Almeida, E. Picano, M. Carrageta, A. D'andrea, R. Cocchia, L. Riegler, E. Golia, R. Scarafile, P. Caso, M. G. Russo, E. Bossone, R. Calabro', H. Noman, A. Adel, A. M. R. Elfaramawy, M. Abdelraouf, W. A. E. L. Elnaggar, E. Baligh, L. Sargento, D. Silva, S. Goncalves, S. Ribeiro, G. Vinhas Sousa, A. Almeida, M. Lopes, M. Rodriguez-Manero, L. Aguado Gil, P. Azcarate, P. Lloret Luna, A. Macias Gallego, S. A. R. A. Castano, M. Garcia, C. Pujol Salvador, J. Barba, P. Redondo, L. Tomasoni, S. Sitia, F. Atzeni, L. Gianturco, C. Ricci, P. Sarzi-Puttini, M. Turiel, V. De Gennaro Colonna, T. Uejima, J. Jaroch, C. Polombo, A. Hughes, D. Vinereanu, A. Evanvelista, G. Leftheriotis, A. G. Fraser, A. Lewczuk, B. Sobkowicz, A. Tomaszuk-Kazberuk, R. Sawicki, T. Hirnle, B. W. Michalski, D. Filipiak, J. D. Kasprzak, P. Lipiec, H. Dalen, O. C. Mjolstad, B. E. Klykken, T. Graven, M. Martensson, M. Olsson, L.-A. Brodin, R. Enache, E. Leiballi, A. Penhall, R. Perry, M. Altman, A. Sinhal, J. Bennetts, D. P. Chew, M. X. Joseph, L. H. Larsen, T. Kristensen, L. V. Kober, K. F. Kofoed, F. Moscoso Costa, R. Ribeiras, J. Brito, S. Boshoff, J. Neves, R. Teles, M. Canada, M. J. Andrade, R. Gouveia, A. Silva, A. Miskovic, T. P. Poerner, C. S. Stiller, B. G. Goebel, A. M. Moritz, L. Stefani, G. G. Galanti, M. Moraldo, C. Bergamini, P. A. Pabari, N. M. Dhutia, A. S. N. Malaweera, K. Willson, J. Davies, A. D. Hughes, X. Y. Xu, D. P. Francis, R. Jasaityte, B. Amundsen, D. Barbosa, D. Loeckx, G. Kiss, F. Orderud, V. Robesyn, P. Claus, J. D'hooge, T. Nao, T. Miura, K. Shams, S. Samir, R. Samir, M. El-Sayed, A. M. Anwar, Y. Nosir, A. Galal, H. Chamsi-Pasha, A. Ciobanu, R. Dulgheru, S. Bennett, A. De Luca, L. Toncelli, F. Cappelli, B. Cappelli, M. C. R. Vono, G. Galanti, Y. Zorman, M. S. Yilmazer, M. Akyildiz, T. Gurol, A. Aydin, B. Dagdeviren, and A. Kalangos

Subjects
medicine.medical_specialty, business.industry, Physical therapy, Medicine, Radiology, Nuclear Medicine and imaging, General Medicine, Session (computer science), Cardiology and Cardiovascular Medicine, business
Published
2010

7. Predictors for myocardial recovery of patients implanted with an ECMO device following myocardial infarction

Author

C. Biedermann, F. Schaerer, Luc-Philippe Christiaens, B. Lequeux, F. Rayed-Pelardy, C. Lacroix, Elisa Larrieu-Ardilouze, T. Kerforne, Pierre Corbi, S. Chauvet, and Michaela B Rehman

Subjects
medicine.medical_specialty, business.industry, Cardiogenic shock, medicine.medical_treatment, medicine.disease, Refractory, Internal medicine, Circulatory system, medicine, Cardiology, Extracorporeal membrane oxygenation, Weaning, Myocardial infarction, Cardiology and Cardiovascular Medicine, Coronary revascularisation, business, Survival rate
Abstract

Introduction Extracorporeal membrane oxygenation (ECMO) has become the most widely used circulatory aid in refractory cardiogenic shock (CS). There is little data available on the predictive markers of a favorable outcome following myocardial infarction. Objective To identify the factors predictive of the successful withdrawal of ECMO implanted for refractory CS of ischemic origin. Methods This was an observational retrospective single-center study. The patients were distributed into two groups: successful (55%) or non successful (45%) ECMO weaning. Results Sixty-five patients were included between January 2008 and March 2017 in the Poitiers University Hospital (CHU). Complete coronary revascularisation was achieved mainly in the in the “successful weaning” group, P = 0.058. The 30-day survival rate was 43%. A history of myocardial infarction, [0.03–0.92, P = 0.039], initial ventricular rhythm disorders (RD) [1.33–19.17, P = 0.018] and the hemoglobin level [0.58–0.96, P = 0.021] were revealed as independent predictive factors for successful weaning from ECMO. Conclusion The early use of ECMO is an effective rescue strategy which provides recovery of myocardial function in close to 55% of cases. The occurrence of de ventricular RD (OR = 5) on admission is predictive of greater survival.

Published
2018

8. Retained knife blade: an unusual cause for headache following massive alcohol intake

Author

E Picquenot, O Lesieur, V Verrier, M Lempereur, and B Lequeux

Subjects
Adult, Male, medicine.medical_specialty, Injury control, Accident prevention, Alcoholic intoxication, Poison control, Case Report, Wounds, Stab, Critical Care and Intensive Care Medicine, Acute alcohol, medicine, Humans, Foreign Bodies, business.industry, Headache, Brain, General Medicine, Surgery, Tomography x ray computed, Brain Injuries, Emergency Medicine, Alcohol intake, Tomography, X-Ray Computed, business, Alcoholic Intoxication
Abstract

Massive alcohol intake usually resolves in a banal headache. We report a case of a patient presenting with acute alcohol intoxication in which the ensuing “hangover” was due to a knife blade deeply retained in the brain parenchyma. This case underlines the unpredictability of retained foreign bodies without a high level of suspicion and a detailed description of the circumstances of admission.

Published
2006

9. Not only E/Ea ratio during exercise but arterial compliance correlates with six-minute walking test in patients with heart failure with normal ejection fraction

Author

B. Lequeux, Philippe Sosner, Luc Christiaens, D. Coisne, and F. Vallet

Subjects
medicine.medical_specialty, Ejection fraction, business.industry, Walking test, General Medicine, medicine.disease, Compliance (physiology), Heart failure, Internal medicine, medicine, Cardiology, cardiovascular system, In patient, business, Cardiology and Cardiovascular Medicine
Full Text
View/download PDF

10. Pre-emptive treatment of heart failure exacerbations in patients managed with the HeartLogic™ algorithm.

Author

Garcia R, Gras D, Mansourati J, Defaye P, Bisson A, Boveda S, Gandjbakhch E, Gras M, Gueffet JP, Himbert C, Jacon P, Khattar P, Lequeux B, Li A, Mansourati V, Minois D, Marijon E, Pierre B, Probst V, and Degand B

Subjects
Humans, Cohort Studies, Stroke Volume, Prospective Studies, Biological Specimen Banks, Ventricular Function, Left, Algorithms, Quality of Life, Heart Failure
Abstract

Aims: Heart failure (HF) is a chronic disease affecting 64 million people worldwide and places a severe burden on society because of its mortality, numerous re-hospitalizations and associated costs. HeartLogic™ is an algorithm programmed into implanted devices incorporating several biometric parameters which aims to predict HF episodes. It provides an index which can be monitored remotely, allowing pre-emptive treatment of congestion to prevent acute decompensation. We aim to assess the impact and security of pre-emptive HF management, guided by the HeartLogic™ index., Methods and Results: The HeartLogic™ France Cohort Study is an investigator-initiated, prospective, multi-centre, non-randomized study. Three hundred ten patients with a history of HF (left ventricular ejection fraction ≤40%; or at least one episode of clinical HF with elevated NT-proBNP ≥450 ng/L) and implanted with a cardioverter defibrillator enabling HeartLogic™ index calculation will be included across 10 French centres. The HeartLogic™ index will be monitored remotely for 12 months and in the event of a HeartLogic™ index ≥16, the local investigator will contact the patient for assessment and adjust HF treatment as necessary. The primary endpoint is unscheduled hospitalization for HF. Secondary endpoints are all-cause mortality, cardiovascular death, HF-related death, unscheduled hospitalizations for ventricular or atrial arrhythmia and HeartLogic™ index evolution over time. Blood samples will be collected for biobanking, and quality of life will be assessed. Finally, the safety of a HeartLogic™-triggered strategy for initiating or increasing diuretic therapy will be assessed. A blind and independent committee will adjudicate the events., Conclusions: The HeartLogic™ France Cohort Study will provide robust real-world data in a cohort of HF patients managed with the HeartLogic™ algorithm allowing pre-emptive treatment of heart failure exacerbations., (© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

11. Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF.

Author

Guenoun M, Cohen S, Villaceque M, Sharareh A, Schwartz J, Hoffman O, Dib JC, Ouazana L, Assouline S, Parrens E, Garban T, Pradeau V, Guedj-Meynier D, Lequeux B, Cohen C, Durand P, Dievart F, Dhanjal TS, Sabouret P, and Lellouche N

Subjects
Humans, Aged, Aged, 80 and over, Rivaroxaban, Anticoagulants, Retrospective Studies, Dabigatran, Registries, Administration, Oral, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy, Atrial Fibrillation complications, Stroke epidemiology, Stroke etiology, Stroke prevention & control, Kidney Failure, Chronic complications
Abstract

Aims: Since the introduction of direct oral anticoagulant (DOAC) for atrial fibrillation (AF) therapy, inappropriate and/or underdosing of these drugs has been a major clinical challenge. We evaluated the characteristics of patients with AF treated with inappropriate and low-dose DOACs., Methods and Results: Patients with AF treated with inappropriate and low-dose DOACs from October 2021 to December 2021 were evaluated from the French National Prospective Registry (PAFF). We evaluated 1890 patients with AF receiving DOACs (apixaban 55%, dabigatran 7%, and rivaroxaban 38%). Inappropriate dosing was noted in 18% of the population. Patients with appropriate dosing had less comorbidities: younger age (75 ± 10 vs. 82 ± 8 years old, P < 0.0001), reduced chronic renal failure (26 vs. 61%, P < 0.0001), and lower CHA2DS2VASc and HASBLED scores (3 ± 2 vs. 4 ± 3, P < 0.0001; 2 ±1 vs. 2 ± 2, P < 0.0001), respectively. In multivariate analysis, older age (P < 0.0001) and a higher CHA2DS2VASc score (P = 0.0056) were independently associated with inappropriate DOAC dosing. Among 472 patients (27%) treated with low-dose rivaroxaban or apixaban, 46% were inappropriately underdosed. Patients inappropriately underdosed were younger (82.3 ± 8.4 vs. 85.9 ± 5.9 years, P < 0.0001) with less chronic renal disease (47 vs. 98%, P < 0.0001). However, these patients had higher rates of prior haemorrhagic events (18 vs. 10%, P = 0.01), clopidogrel use (11 vs. 3%, P = 0.0002), and apixaban prescription (74 vs. 50%, P < 0.0001)., Conclusion: Within this large registry, DOACs were associated with inappropriate dosing in 18% of cases. Independent predictors of inappropriate dosing were high CHA2DS2VASc scores and older age. Moreover, 46% of patients treated with low-dose DOACs were inappropriately underdosed and more frequently in patients treated with apixaban., Competing Interests: Conflict of interest: N.L. received consulting fees from Bayer and BMS-Pfizer., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2023
Full Text
View/download PDF

12. Optimisation of treatments for heart failure with reduced ejection fraction in routine practice: a position statement from a panel of experts.

Author

Girerd N, Leclercq C, Hanon O, Bayés-Genís A, Januzzi JL, Damy T, Lequeux B, Meune C, Sabouret P, and Roubille F

Subjects
Humans, Stroke Volume, Heart Failure drug therapy, Ventricular Dysfunction, Left
Abstract

Major international practice guidelines recommend the use of a combination of 4 medication classes in the treatment of patients with heart failure with reduced ejection fraction (HFrEF) but do not specify how these treatments should be introduced and up-titrated. Consequently, many patients with HFrEF do not receive an optimized treatment regimen. This review proposes a pragmatic algorithm for treatment optimization designed to be easily applied in routine practice. The first goal is to ensure that all 4 recommended medication classes are initiated as early as possible to establish effective therapy, even at a low dose. This is considered preferable to starting fewer medications at a maximum dose. The second goal is to ensure that the intervals between the introduction of different medications and between different titration steps are as short as possible to ensure patient safety. Specific proposals are made for older patients (> 75 years) who are frail, and for those with cardiac rhythm disorders. Application of this algorithm should allow an optimal treatment protocol to be achieved within 2-months in most patients, which should the treatment goal in HFrEF., (Copyright © 2023. Published by Elsevier España, S.L.U.)

Published
2023
Full Text
View/download PDF

13. PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic heart failure in primary care (PREFER): a real-world study.

Author

Hobbs FR, Hussain RI, Vitale C, Pinto YM, Bueno H, Lequeux B, Pauschinger M, Obermeier M, Ferber PC, and Gustafsson F

Subjects
Aged, Europe epidemiology, Female, Follow-Up Studies, Heart Failure epidemiology, Heart Failure therapy, Hospitalization trends, Humans, Incidence, Male, Prospective Studies, Protein Precursors, Survival Rate trends, Heart Failure blood, Natriuretic Peptide, Brain blood, Peptide Fragments blood, Primary Health Care methods, Referral and Consultation
Abstract

Objective: To assess current management practice of heart failure with reduced ejection fraction (HFrEF) in multinational primary care (PC) and determine whether N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP)-guided referral of HFrEF patients from PC to a cardiologist could improve care, defined as adherence to European Society of Cardiology (ESC) guideline-recommended pharmacotherapy., Methods: PRospective Evaluation of natriuretic peptide-based reFERral of patients with chronic HF in PC (PREFER) study enrolled HFrEF patients from PC considered clinically stable and those with NT-pro-BNP ≥600 pg/mL were referred to a cardiologist for optimisation of HF treatment. The primary outcome of adherence to ESC HF guidelines after referral to specialist was assessed at the second visit within 4 weeks of cardiologist's referral and no later than 6 months after the baseline visit. Based on futility interim analysis, the study was terminated early., Results: In total, 1415 HFrEF patients from 223 PCs from 18 countries in Europe were enrolled. Of these, 1324 (96.9%) were considered clinically stable and 920 (65.0%) had NT-pro-BNP ≥600 pg/mL (mean: 2631 pg/mL). In total, 861 (60.8%) patients fulfilled both criteria and were referred to a cardiologist. Before cardiologist consultation, 10.1% of patients were on ESC guideline-recommended HFrEF medications and 2.7% were on recommended dosages of HFrEF medication (defined as ≥50% of ESC guideline-recommended dose). Postreferral, prescribed HFrEF drugs remained largely unchanged except for an increase in diuretics (+4.6%) and mineralocorticoid receptor antagonists (+7.9%). No significant increase in patients' adherence to guideline-defined drug combinations (11.2% post-referral vs 10.1% baseline) or drug combinations and dosages (3.3% postreferral vs 2.7% baseline) was observed after cardiologist consultation., Conclusions: PREFER demonstrates substantial suboptimal treatment of HFrEF patients in the real world. Referral of patients with elevated NT-pro-BNP levels from PC to cardiologist did not result in meaningful treatment optimisation for treatments with known mortality and morbidity benefit., Competing Interests: Competing interests: RH acknowledges his part-funding from the National Institute for Health Research (NIHR) School for Primary Care Research, the NIHR Collaboration for Leadership in Health Research and Care (CLARHC) Oxford, the NIHR Oxford Biomedical Research Centre (BRC, UHT), and the NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative (MIC) and has received occasional fees for consulting or speaking from companies including Novartis. RH and PF are employees of Novartis. HB receives research funding from the Instituto de Salud Carlos III, Spain (PIE16/00021 & PI17/01799), Astra-Zeneca, BMS, Janssen and Novartis and has received consulting fees from Astra-Zeneca, Bayer, BMS-Pfizer, Novartis; and speaking fees or support for attending scientific meetings from Astra-Zeneca, Bayer, BMS-Pfizer, Novartis, and MEDSCAPE-the heart.og. YMP received consultancy fees from Novartis, Roche Diagnostics and holds minority shares in a University spin-off. FG has received fees for consulting and speaking honoraria from Novartis, Carmat, Orion and fees for consulting, speaking and as an investigator from Abbott. He has also received research grant from Orion and speaking honoraria from Boehringer-Ingelheim and received fees for consulting from Bayer and Pfizer. MO has been contracted by Novartis., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2021
Full Text
View/download PDF

14. First symptoms and health care pathways in hospitalized patients with acute heart failure: ICPS2 survey. A report from the Heart Failure Working Group (GICC) of the French Society of Cardiology.

Author

Beauvais F, Tartière L, Pezel T, Motet C, Aumont MC, Baudry G, Eicher JC, Galinier M, Gellen B, Guihaire J, Legallois D, Lequeux B, Mika D, Mouquet F, Salvat M, Taieb C, Zorès F, Berthelot E, and Damy T

Subjects
Acute Disease, Aged, Delivery of Health Care, Hospitalization, Humans, Male, Cardiology, Heart Failure diagnosis, Heart Failure epidemiology, Heart Failure therapy
Abstract

Background: Acute heart failure (AHF) is a common serious condition that contributes to about 5% of all emergency hospital admissions in Europe., Hypothesis: To assess the type and chronology of the first AHF symptoms before hospitalization and to examine the French healthcare system pathways before, during and after hospitalization., Material and Methods: A retrospective observational study including patients hospitalized for AHF RESULTS: 793 patients were included, 59.0% were men, 45.6% identified heart failure (HF) as the main cause of hospitalization; 36.0% were unaware of their HF. Mean age was 72.9 ± 14.5 years. The symptoms occurring the most before hospitalization were dyspnea (64.7%) and lower limb edema (27.7%). Prior to hospitalization, 47% had already experienced symptoms for 15 days; 32% of them for 2 months. Referral to hospital was made by the emergency medical assistance service (SAMU, 41.6%), a general practitioner (GP, 22.3%), a cardiologist (19.5%), or the patient (16.6%). The modality of referral depended more on symptom acuteness than on type of symptoms. A sudden onset of AHF symptoms led to making an emergency call or to spontaneously attending an emergency room (ER), whereas cardiologists were consulted when symptoms had already been present for over 15 days. Cardiologists referred more patients to cardiology departments and fewer patients to the ER than general practitioners or the SAMU., Conclusion: This study described the French healthcare system pathways before, during and after hospitalization AHF. AHF clinic network should be developed to provide adequate care for all HF patients and create awareness regarding AHF symptoms., (© 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.)

Published
2021
Full Text
View/download PDF

15. Does resting heart rate measured by the physician reflect the patient's true resting heart rate? White-coat heart rate.

Author

Lequeux B, Uzan C, and Rehman MB

Subjects
Blood Pressure physiology, Female, France epidemiology, Humans, Incidence, Male, Middle Aged, Pilot Projects, Prospective Studies, White Coat Hypertension diagnosis, White Coat Hypertension epidemiology, Heart Rate physiology, Physician-Patient Relations, Physicians, Rest physiology, White Coat Hypertension physiopathology
Abstract

Objectives: In cardiology, resting heart rate (HR) and blood pressure (BP) are key elements and are used to adapt treatment. However HR measured in consultation may not reflect true resting HR. We hypothesize that there may be a "white-coat" effect like with BP and that there may be an association between HR variations and BP variations., Methods: This prospective, monocentric, observational, pilot study (January-April 2016) included 57 consecutive ambulatory patients at Poitiers University Hospital, France (58% male, mean age 64 years). Patients' resting HR and BP were recorded with the same automated blood pressure sphygmomanometer in consultation by the physician then with self-measurement at home., Results: In the overall cohort, we found that HR was significantly higher in consultation (70.5bpm±12.6 vs. 68.1bpm±10.1, p=0.034). HR also correlated with diastolic BP (r=0.45, p=0.001). Patients were divided into three groups to look for associations with BP: masked HR, (higher HR at home, 38.6%), white-coat HR, (lower HR at home 52.6%) and iso HR, (no change between HR at home and consultation, 8.8%). Although there was no difference between groups in diastolic BP measured in consultation, home diastolic BP was lower in the white-coat HR group (74.3mmHg±9.8 vs. 77.9mmHg±7.5, p=0.016)., Conclusions: Our study brings to light an exciting idea that could have a major therapeutic and maybe prognostic impact in cardiology: resting HR measured by the physician in consultation does not reflect true resting HR. This must be taken into account to adapt treatment., (Copyright © 2017. Published by Elsevier B.V.)

Published
2018
Full Text
View/download PDF

16. Snoring but not sleepiness is associated with increased aortic root diameter in hypertensive patients. The SLEEPART study.

Author

Baguet JP, Courand PY, Lequeux B, Delsart P, Barber-Chamoux N, Sosner P, Baguet S, and Lopez-Sublet M

Subjects
Adult, Aged, Disorders of Excessive Somnolence complications, Female, Humans, Hypertension complications, Male, Middle Aged, Sleep Apnea Syndromes complications, Sleep Stages physiology, Snoring complications, Aorta pathology, Disorders of Excessive Somnolence diagnosis, Hypertension diagnosis, Sleep Apnea Syndromes diagnosis, Snoring diagnosis
Published
2016
Full Text
View/download PDF

17. [Physical activity level and home blood pressure measurement: Pilot study "Acti-HTA"].

Author

Sosner P, Ott J, Steichen O, Bally S, Krummel T, Brucker M, Lequeux B, Dourmap C, Llaty P, Le Coz S, Baguet S, Miranne A, Labrunée M, Gremeaux V, and Lopez-Sublet M

Subjects
Female, Humans, Male, Middle Aged, Pilot Projects, Surveys and Questionnaires, Blood Pressure Monitoring, Ambulatory, Hypertension diagnosis, Hypertension therapy, Motor Activity
Abstract

While physical activity (PA) is recommended for high blood pressure management, the level of PA practice of hypertensive patients remains unclear. We aimed to assess the association between the level of both PA and blood pressure of individuals consulting in 9 hypertension specialist centres. Eighty-five hypertensive patients were included (59 ± 14 years, 61% men, 12% smokers, 29% with diabetes). Following their consultation, they performed home blood pressure measurement (HBPM) over 7 days (2 in the morning+2 in the evening), they wrote in a dedicated form their daily activities to estimate the additional caloric expenditure using Acti-MET device (built from International physical Activity Questionnaire [IPAQ]). Thus, patients completed a self-administered questionnaire "score of Dijon" (distinguishing active subjects with a score>20/30, from sedentary<10/30). Subjects with normal HBPM value (<135/85 mm Hg) (55% of them) compared to those with high HBPM were older, had a non-significant trend towards higher weekly caloric expenditure (4959 ± 5045 kcal/week vs. 4048 ± 4199 kcal/week, P=0.3755) and score of Dijon (19.44 ± 5.81 vs. 18.00 ± 4.32, P=0.2094) with a higher proportion of "active" subjects (48.9% vs. 34.2%, P=0.1773). In conclusion, our results demonstrate a "tendency" to a higher level of reported PA for subjects whose hypertension was controlled. This encourages us to continue with a study that would include more subjects, which would assess PA level using an objective method such as wearing an accelerometer sensor., (Copyright © 2015 Elsevier Masson SAS. All rights reserved.)

Published
2015
Full Text
View/download PDF

18. A new method for measurement of left atrial volumes using 64-slice spiral computed tomography: comparison with two-dimensional echocardiographic techniques.

Author

Christiaens L, Lequeux B, Ardilouze P, Ragot S, Mergy J, Herpin D, Bonnet B, and Allal J

Subjects
Adult, Aged, Cardiovascular Diseases diagnostic imaging, Cardiovascular Diseases pathology, Echocardiography trends, Female, Heart Atria pathology, Humans, Male, Middle Aged, Organ Size, Prospective Studies, Tomography, Spiral Computed trends, Echocardiography methods, Heart Atria diagnostic imaging, Tomography, Spiral Computed methods
Abstract

Background: Left atrial (LA) volume, is related to cardiovascular morbidity. LA enlargement is usually assessed using trans-thoracic echocardiography (TTE). The association of modern multislice computed tomography (MSCT) imaging and new 3D reconstruction software, allows direct cardiac chamber volume measurement without geometrical assumptions. This study was designed to evaluate the maximal (LAmax) and minimal (LAmin) LA volumes during the cardiac cycle using MSCT and TTE approaches., Methods: We screened 26 consecutive patients referred for coronary imaging using a 64-MSCT scanner and a TTE within 12 h. Contiguous multiphase images were generated from axial MSCT data and semi-automated 3D segmentation technique was applied to generate LA volumes. Using TTE, LA volumes and LA ejection fraction (LAEF) were obtained using five assumptions methods: cubing equation, diameter-length formula, area-length formula, ellipsoidal formula and biplane Simpson rule., Results: Five patients were excluded for inadequate TTE visualization and one for ectopic beats during MSCT. The sample consisted in 20 patients (11 men, age: 56+/-14 years). Using MSCT, LA volumes indexed to body surface area were: LAmax=74+/-27 ml/m(2), LAmin=49+/-26 ml/m(2), with close correlations with TTE measurements and a significant underestimation by all TTE approaches. A close correlation was observed between LAEF using MSCT and TTE Simpson's method: 36+/-14% vs. 37+/-14%, r=0.99, p<0.0001., Conclusion: Theses results suggest that the assessment of LA volumes and ejection fraction was reliable using 64-MSCT in patients referred for coronary computed tomography imaging.

Published
2009
Full Text
View/download PDF

19. Retained knife blade: an unusual cause for headache following massive alcohol intake.

Author

Lesieur O, Verrier V, Lequeux B, Lempereur M, and Picquenot E

Subjects
Adult, Foreign Bodies diagnostic imaging, Humans, Male, Tomography, X-Ray Computed, Alcoholic Intoxication complications, Brain diagnostic imaging, Brain Injuries complications, Foreign Bodies complications, Headache etiology, Wounds, Stab complications
Abstract

Massive alcohol intake usually resolves in a banal headache. We report a case of a patient presenting with acute alcohol intoxication in which the ensuing "hangover" was due to a knife blade deeply retained in the brain parenchyma. This case underlines the unpredictability of retained foreign bodies without a high level of suspicion and a detailed description of the circumstances of admission.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results